No Data
Yestar Healthcare Appoints CFO
Change in Chief Financial Officer of Star Medical (02393.HK)
Jiuxing Medical (02393.HK) announced that Wang Hong has resigned as an executive director, CFO, authorized representative under Rule 3.05 of the Listing Rules of the Stock Exchange, and a member of the Investment Committee under the board of directors to dedicate more time to family care from today (15th). Wang Hong will continue to serve the group in his new role as a senior consultant. The board of directors further announced that Qiao Jinrong has been appointed as an executive director, CFO, member of the Investment Committee, and authorized representative, effective on the same day.
yestar health (02393.HK): Qiao Jinrong was appointed as an executive director.
Great Wisdom News on October 15th, yestar health (02393.HK) announced that Mr. Wang Hong has resigned as the company's executive director, CFO, authorized representative, and a member of the investment committee under the board of directors, in order to devote more time to family care, effective from October 15, 2024. Ms. Wang will continue to serve the group in the new role of senior advisor. In addition, Mr. Qiao Jinrong has been appointed as the company's executive director, effective from October 15, 2024.
YESTAR HEALTH: Interim report 2024
YESTAR HEALTH: INTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2024
Hong Kong stocks soared with Star Creep Medical jumping by 123%, expecting a significant increase in mid-term net profit.
On August 19, Gelonghui: Giant Star Medical (2393.HK) surged 123.68% to HKD 0.085 in early trading, but the gain quickly narrowed to around 70%. However, it remains the stock with the largest increase in the Hong Kong stock market, but the trading volume is light, with only HKD 2.67 million turnover so far. The Group announced that its comprehensive net profit for the first half of the year is estimated to increase by no less than CNY 1.05 billion, or CNY 11.6 million, due to the redemption of the original 2026 maturity preference notes at a discount, which confirmed a considerable premium. At the same time, the redemption of relevant preference notes reduced financial costs.
No Data
No Data